RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.
Study identifier: NCT07002034. Status: RECRUITING. Phase: PHASE2.
Eligibility
Criteria: Inclusion Criteria: * Has a ≥4 week history of AjD as defined by DSM-5-TR with either depressed mood, or mixed anxiety and depressed mood confirmed by clinical interview with evidence that the AjD was instigated by one of the following medical illnesses (e.g., diagnosis, impact, management, recurrence, prognosis): Cancer, ALS, MS, PD or IPF * Is sufficiently ambulatory and capable of self care as necessary to complete study procedures * Has normal cognitive function * Is on stable use of antidepressants or psychotherapy, or is willing to delay use until the end of study * If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant * Is willing and able to comply with the conditions and requirements of the study Exclusion Criteria: * Has a significant risk of suicide * Has active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder * Has active or a history of central nervous system malignancy * Has other medically significant conditions rendering unsuitability for the study * Has used or will need to use prohibited medications or therapies * Has a known sensitivity or intolerance to study intervention or potential rescue medications
- Minimum age: 18 Years
- Maximum age: 80 Years
Participating locations
- UAB, Psychiatry and Behavioral Neurology, Birmingham, Alabama
- University of Arizona, Tucson, Arizona
- Kadima Neuropsychiatry Institute, San Diego, California
- Providence Medical Foundation, Santa Rosa, California
- University of Colorado, Aurora, Colorado
- University of South Florida, Department of Psychiatry and Behavioral Neuroscience, Tampa, Florida
- Emory University, Atlanta, Georgia
- Hawaii Pacific Neuroscience, Honolulu, Hawaii
- Rush University Medical Center, Chicago, Illinois
- University of Chicago Medical Center, Chicago, Illinois
Study records are sourced from ClinicalTrials.gov. Confirm current eligibility, recruiting status, and locations in the official record.